These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25453311)

  • 1. [Update of recommendations on the use of palivizumab as prophylaxis in RSV infections].
    Figueras Aloy J; Carbonell Estrany X;
    An Pediatr (Barc); 2015 Mar; 82(3):199.e1-2. PubMed ID: 25453311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility for palivizumab prophylaxis in a cohort of children with severe bronchiolitis.
    Hasegawa K; Mansbach JM; Piedra PA; Dunn MB; Clark S; Sullivan AF; Camargo CA
    Pediatr Int; 2015 Oct; 57(5):1031-4. PubMed ID: 26508190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).
    Bollani L; Baraldi E; Chirico G; Dotta A; Lanari M; Del Vecchio A; Manzoni P; Boldrini A; Paolillo P; Di Fabio S; Orfeo L; Stronati M; Romagnoli C;
    Ital J Pediatr; 2015 Dec; 41():97. PubMed ID: 26670908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].
    Sánchez Luna M; Pérez Muñuzuri A; Leante Castellanos JL; Ruiz Campillo CW; Sanz López E; Benavente Fernández I; Sánchez Redondo MD; Rite Gracia S;
    An Pediatr (Engl Ed); 2019 Nov; 91(5):348-350. PubMed ID: 31585838
    [No Abstract]   [Full Text] [Related]  

  • 6. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
    Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
    Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
    Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of Palivizumab in the NICU.
    Vendetti N; Gerber JS; Sammons JS; Fisher BT; Zaoutis TE; Coffin SE
    Hosp Pediatr; 2016 Jun; 6(6):354-8. PubMed ID: 27164941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to the 2014 American Academy of Pediatrics palivizumab prophylaxis recommendations.
    Sierra CM; Park A; Eum E; Garcia G; Lopez M; Daniel SN; Bahjri K; Parbuoni KA
    Pediatr Pulmonol; 2021 May; 56(5):1121-1126. PubMed ID: 33314771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis.
    Sánchez-Solis M; Gartner S; Bosch-Gimenez V; Garcia-Marcos L
    Allergol Immunopathol (Madr); 2015; 43(3):298-303. PubMed ID: 24231153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
    Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD
    Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
    Zembles TN; Gaertner KM; Gutzeit MF; Willoughby RE
    Am J Health Syst Pharm; 2016 Mar; 73(6):405-8. PubMed ID: 26953285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)].
    Figueras Aloy J; Carbonell Estrany X;
    An Pediatr (Barc); 2010 Aug; 73(2):98.e1-4. PubMed ID: 20621574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age.
    Zembles TN; Bushee GM; Willoughby RE
    J Pediatr; 2019 Jun; 209():125-129. PubMed ID: 30952507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.